

NDA 022387/S-028

SUPPLEMENT APPROVAL

United Therapeutics Corp.
Attention: Nicole Wilkerson
Director, Regulatory Affairs
55 T.W. Alexander Drive
P.O. Box 14186
Research Triangle Park, NC 27709

Dear Nicole Wilkerson:

Please refer to your supplemental new drug application (sNDA) dated and received November 7, 2025, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tyvaso (treprostinil) Inhalation Solution.

This Prior Approval sNDA provides for the following changes to the Instructions For Use (IFU) document:

- Removal of the indication statement per the FDA Guidance Instructions for Use Patient Labeling for Human Prescription Drug and Biological Products Content and Format Guidance for Industry (July 2022)
- Updating the nomenclature for “Patient Information” to “Prescribing Information” for consistency in language with FDA’s removal of the Patient Information Leaflet from approved patient labeling with the approval of S-017 (March 31, 2021).
- Additional minor changes (update to UTC’s city and zip code; update to area code for UTC’s contact number) were noted.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (Instructions for Use), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

If you have any questions, contact Lori Anne Wachter, RN, BSN, RAC, Regulatory Project Manager for Safety, at 301 796-3975 or lori.wachter@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Selena DeConti, PharmD, MPH
Deputy Director for Safety
Division of Cardiology and Nephrology
Office of Cardiology, Hematology, Endocrinology
and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SELENA D DECONTI
04/03/2026 01:41:35 PM